Industry

Some patients on cancer therapy may have increased risk for uveitis

Healio Optometry2d ago1 min read

FORT LAUDERDALE, Fla. — Patients being treated with immune checkpoint inhibitors may be at higher risk for developing uveitis, according to a speaker at Retina World Congress.Charlie Zhang, MD, said uveitis has been an uncommon side effect of cancer treatment, but there has been a shift as the use of immune checkpoint inhibitors (ICIs) has become more common.“Clinically, the major adverse effects of these drugs is the spectrum of immune-related adverse dysregulation, with the eye being one of the many organs affected,” Zhang said.Zhang and colleagues analyzed data from 157,493 patients on ICI

Read full article on Healio Optometry

AI Summary

Quick Take

A large-scale analysis of over 157,000 patients presented at the Retina World Congress indicates that the rising use of immune checkpoint inhibitors (ICIs) in oncology is driving an increased incidence of uveitis. While historically considered an uncommon side effect of cancer therapy, these drugs can trigger systemic immune-related adverse dysregulation that frequently manifests in the eye.

Why It Matters

As ICIs become the standard of care for various malignancies, eye care providers are likely to see a higher volume of drug-induced inflammatory conditions. This shift requires a high index of suspicion when treating oncology patients who present with new-onset ocular symptoms. Understanding the link between systemic immunotherapy and ocular inflammation is critical for timely intervention, as these cases represent a specific subset of immune-related adverse events that can impact both vision and the patient's cancer treatment trajectory.

Key Findings

The use of immune checkpoint inhibitors (ICIs) is associated with a heightened risk of developing uveitis compared to historical cancer treatments.
Ocular inflammation is identified as a key component of the spectrum of immune-related adverse dysregulation caused by these therapies.
The study analyzed a significant cohort of 157,493 patients to identify the shift in adverse effect profiles as ICIs become more common in clinical practice.

Study Snapshot

Design

Retrospective data analysis

Population

Patients undergoing cancer treatment with immune checkpoint inhibitors

Sample Size

157,493 patients

Practice Implications

Clinicians should routinely screen oncology patients for the use of ICIs and maintain a high suspicion for uveitis in this population. Any patient on immunotherapy presenting with blurred vision, pain, or photophobia requires a prompt dilated exam to manage potential ocular inflammation and coordinate care with the treating oncologist.

Who's Affected

Retina SpecialistsUveitis SpecialistsComprehensive OphthalmologistsOptometrists

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.